An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential
Jay S, Murthy A, Hawkins J, Wortzel J, Steinhauser M, Alvarez L, Gannon J, Macrae C, Griffith L, Lee R. An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential. Circulation 2013, 128: 152-161. PMID: 23757312, PMCID: PMC3753575, DOI: 10.1161/circulationaha.113.002203.Peer-Reviewed Original ResearchConceptsNeonatal rat cardiomyocytesRat cardiomyocytesCumulative dose-dependent cardiotoxicityDOXO-induced cardiomyopathyInduced pluripotent stem cellsDose-dependent cardiotoxicityImprove cardiac functionDOXO-induced cardiotoxicityDoxorubicin-induced cardiotoxicityPluripotent stem cellsPromote cardiomyocyte survivalMaltose-binding protein fusionEpidermal growth factor-like domainsFractional shorteningProneoplastic effectsCardiomyopathy modelGrowth factor-like domainCardiac functionEffective anthracyclineHuman cardiomyocytesFactor-like domainCardioprotective agentCancer cellsStem cellsCardiotoxicity